The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -27.27 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -0.51 — flag raised, worth a closer lookWatch
- Earnings quality 63/100 — worth a closer lookWatch
Leadership changes
From Cue Biopharma, Inc.'s own filings, the day they're filed.
- Michael Meluzio · President · appointmenteff. 2026-06-01
- Sumita Ray · Chief Legal & Compliance Officer · appointmenteff. 2026-06-01
- Daniel Camardo · directors · departureeff. 2026-05-30
Latest filings
- 8-K · Company announcement2026-06-03
- 8-K · Company announcement2026-06-02
- DEF 14A · Annual proxy (pay & governance)2026-05-21
- 10-Q · Quarterly report2026-05-14
- 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Cue Biopharma, Inc., every answer cited🔒
- The Intelligence Brief — added when Cue Biopharma, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.